Candriam S.C.A. Buys New Holdings in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Candriam S.C.A. has acquired a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH), purchasing 248,610 shares valued at approximately $4.51 million.
• Dianthus reported a quarterly loss of ($0.88) earnings per share, missing estimates, and has a negative net margin of 2,364.56%.
• The current consensus rating for Dianthus Therapeutics is a Buy with an average price target of $54.00, supported by coverage from multiple analysts.

Candriam S.C.A. acquired a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund acquired 248,610 shares of the company's stock, valued at approximately $4,510,000. Candriam S.C.A. owned 0.77% of Dianthus Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DNTH. TCG Crossover Management LLC bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at $32,735,000. Braidwell LP increased its stake in Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock worth $26,304,000 after acquiring an additional 712,902 shares during the last quarter. Vestal Point Capital LP increased its stake in Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock worth $23,435,000 after acquiring an additional 680,000 shares during the last quarter. Octagon Capital Advisors LP increased its stake in Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after acquiring an additional 363,500 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new position in Dianthus Therapeutics in the 4th quarter worth about $3,924,000. 47.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of research analyst reports. Robert W. Baird decreased their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Wedbush upped their target price on Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. William Blair began coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Seven equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Dianthus Therapeutics currently has an average rating of "Buy" and a consensus price target of $54.00.

Dianthus Therapeutics Stock Performance

DNTH stock traded up $0.92 during trading on Tuesday, hitting $24.33. 304,783 shares of the company traded hands, compared to its average volume of 323,505. The firm has a market capitalization of $783.18 million, a PE ratio of -7.49 and a beta of 1.43. Dianthus Therapeutics, Inc. has a 1 year low of $13.36 and a 1 year high of $32.27. The company has a 50-day moving average of $20.05 and a 200-day moving average of $19.99.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The company had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.